arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

Rezolute, Inc.

RZLT
$3.65 ▼ -0.31 (-7.84%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
66 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Rezolute, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -16.9% ↘
FCF / Share None
Trailing P/E —
Price / Book 3.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

66-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-20.49M
↑ +16.0% —
FCF / Share Free cash flow per share
$-0.13
↑ +32.6% —
Long-Term Debt Long-term obligations
$14.29M
↑ +0.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
10
Cash Quality ↓
54

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 17 years · 66 quarters